Arena Pharmaceuticals Inc., of San Diego, said it started dosing in a phase Ib trial of APD334, an oral candidate designed to target sphingosine 1-phosphate subtype receptor for treating autoimmune diseases. The study will evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses in up to 96 healthy adult volunteers.